Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 3
2004 9
2005 5
2006 5
2007 5
2008 3
2009 7
2010 4
2011 3
2014 1
2015 2
2016 1
2017 3
2018 2
2019 6
2020 10
2021 15
2022 16
2023 13
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. Heath PT, et al. N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30. N Engl J Med. 2021. PMID: 34192426 Free PMC article. Clinical Trial.
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
Sullivan AK, Saunders J, Desai M, Cartier A, Mitchell HD, Jaffer S, Ogaz D, Chiavenna C, Charlett A, Diamente V, Golombek R, Manavi K, Priestley C, Waters LJ, Milinkovic A, McOwan A, Estcourt C, Sabin CA, Rodger A, Gold D, Gazzard BG, McCormack S, Gill ON; Impact Study Group. Sullivan AK, et al. Among authors: milinkovic a. Lancet HIV. 2023 Dec;10(12):e790-e806. doi: 10.1016/S2352-3018(23)00256-4. Lancet HIV. 2023. PMID: 38040478 Free PMC article.
HIV integrase inhibitors: a new era in the treatment of HIV.
Blanco JL, Whitlock G, Milinkovic A, Moyle G. Blanco JL, et al. Among authors: milinkovic a. Expert Opin Pharmacother. 2015 Jun;16(9):1313-24. doi: 10.1517/14656566.2015.1044436. Expert Opin Pharmacother. 2015. PMID: 26001181 Review.
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O'Hara J, McFarlane LR, Lemm NM, McKay PF, Rampling T, Yim YTN, Milinkovic A, Kingsley C, Cole T, Fagerbrink S, Aban M, Tanaka M, Mehdipour S, Robbins A, Budd W, Faust SN, Hassanin H, Cosgrove CA, Winston A, Fidler S, Dunn DT, McCormack S, Shattock RJ; COVAC1 study Group. Pollock KM, et al. Among authors: milinkovic a. EClinicalMedicine. 2022 Feb;44:101262. doi: 10.1016/j.eclinm.2021.101262. Epub 2022 Jan 14. EClinicalMedicine. 2022. PMID: 35043093 Free PMC article.
Nevirapine in the treatment of HIV.
Milinkovic A, Martínez E. Milinkovic A, et al. Expert Rev Anti Infect Ther. 2004 Jun;2(3):367-73. doi: 10.1586/14787210.2.3.367. Expert Rev Anti Infect Ther. 2004. PMID: 15482202 Review.
Cardiometabolic health in people with HIV: expert consensus review.
Batterham RL, Bedimo RJ, Diaz RS, Guaraldi G, Lo J, Martínez E, McComsey GA, Milinkovic A, Naito T, Noe S, O'Shea D, Paredes R, Schapiro JM, Sulkowski MS, Venter F, Waters L, Yoruk IU, Young B. Batterham RL, et al. Among authors: milinkovic a. J Antimicrob Chemother. 2024 Jun 3;79(6):1218-1233. doi: 10.1093/jac/dkae116. J Antimicrob Chemother. 2024. PMID: 38656584 Free PMC article. Review.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat, BicTnT.
Whitlock G, Fidler S, Clarke A, Kang S, Xhikola A, Milinkovic A, Soler-Carracedo A, Henderson M, Adams T, Jahan I, Khawaja A, Taylor G, Boffito M. Whitlock G, et al. Among authors: milinkovic a. HIV Res Clin Pract. 2024 Dec;25(1):2400453. doi: 10.1080/25787489.2024.2400453. Epub 2024 Sep 8. HIV Res Clin Pract. 2024. PMID: 39244669 Free article. Clinical Trial.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
111 results